HC Wainwright set a $9.00 price objective on Vical Incorporated (NASDAQ:VICL) in a report released on Wednesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

Separately, Rodman & Renshaw reaffirmed a buy rating and set a $9.00 target price on shares of Vical in a research report on Monday, June 12th.

Shares of Vical (VICL) traded down 1.6488% during midday trading on Wednesday, hitting $2.3801. The company had a trading volume of 38,428 shares. Vical has a one year low of $2.05 and a one year high of $4.50. The stock’s 50-day moving average price is $2.61 and its 200-day moving average price is $2.34. The stock’s market capitalization is $26.41 million.

Vical (NASDAQ:VICL) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. The company had revenue of $3.42 million for the quarter, compared to the consensus estimate of $3.35 million. Vical had a negative return on equity of 26.09% and a negative net margin of 92.02%. Analysts predict that Vical will post ($1.05) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://theolympiareport.com/2017/08/12/hc-wainwright-analysts-give-vical-incorporated-nasdaqvicl-a-9-00-price-target.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC raised its position in shares of Vical by 9.9% in the fourth quarter. Renaissance Technologies LLC now owns 392,509 shares of the biotechnology company’s stock valued at $903,000 after buying an additional 35,500 shares in the last quarter. FMR LLC raised its position in shares of Vical by 1.8% in the fourth quarter. FMR LLC now owns 1,006,875 shares of the biotechnology company’s stock valued at $2,316,000 after buying an additional 17,967 shares in the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Vical by 83.6% in the second quarter. New York State Common Retirement Fund now owns 130,706 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 59,504 shares in the last quarter. 23.65% of the stock is owned by institutional investors and hedge funds.

About Vical

Receive News & Ratings for Vical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.